Abstract:Pediatric obesity is a chronic and growing problem for which new ideas about the biologic basis of obesity offer hope for effective solutions. Prevalence of pediatric and adult obesity is increasing despite a bewildering array of treatment programs and severe psychosocial and economic costs. The definition of obesity as an increase in fat mass, not just an increase in body weight, has profound influence on the understanding and treatment of obesity. In principle, body weight is determined by a balance between energy expenditure and energy intake, but this observation does not by itself explain obesity. There is surprisingly little evidence that the obese overeat and only some evidence that the obese are more sedentary. Understanding of the biologic basis of obesity has grown rapidly in the last few years, especially with the identification of a novel endocrine pathway involving the adipose tissue secreted hormone leptin and the leptin receptor that is expressed in the hypothalamus. Plasma leptin levels are strongly correlated with body fat mass and are regulated by feeding and fasting, insulin, glucocorticoids, and other factors, consistent with the hypothesis that leptin is involved in body weight regulation and may even be a satiety factor (Fig. 2, Table 1). Leptin injections have been shown to reduce body weight of primates, although human clinical trials will not be reported until summer 1997. So many peptides influencing feeding have been described that one or more may have therapeutic potential (Fig. 2, Table 1). Although the complexity of pathways regulating body weight homeostasis slowed the pace of understanding underlying mechanisms, these complexities now offer many possibilities for novel therapeutic interventions (Fig. 2). Obesity is a major risk factor for insulin resistance and diabetes, hypertension, cancer, gallbladder disease, and atherosclerosis. In particular, adults who were obese as children have increased mortality independent of adult weight. Thus, prevention programs for children and adolescents will have long-term benefits. Treatment programs focus on modification of energy intake and expenditure through decreased calorie intake and exercise programs. Behavior-modification programs have been developed to increase effectiveness of these intake and exercise programs. These programs can produce short-term weight loss. Long-term losses are more modest but achieved more successfully in children than in adults. Several drug therapies for obesity treatment recently have been approved for adults that produce sustained 5% to 10% weight losses but experience with their use in children is limited. Identification of the biochemical pathways causing obesity by genetic approaches could provide the theoretic foundation for novel, safe, and effective obesity treatments. The cloning of leptin in 1994 has already led to testing the efficacy of leptin in clinical trials that are now underway. Although novel treatments of obesity are being developed as a result of the new biology of obesity, prevention of obesity remains an important goal.

Rare genetic forms of obesity in childhood and adolescence: A narrative review of the main treatment options with a focus on innovative pharmacological therapies

Syndromic and Monogenic Obesity: New Opportunities Due to Genetic-Based Pharmacological Treatment

Rare Genetic Forms of Obesity: Clinical Approach and Current Treatments in 2016

[A Clinical Challenge of Evaluation and Management in Children with Genetic Obesity].

Rare genetic forms of obesity: From gene to therapy

Mendelian obesity, molecular pathways and pharmacological therapies: a review

Diagnostic and therapeutic odyssey of two patients with compound heterozygous leptin receptor deficiency

Latest approaches for the treatment of obesity

A comprehensive review of genetic causes of obesity

Updates on Monogenic Obesity in a Multifactorial Disease

Obesity: exploring its connection to brain function through genetic and genomic perspectives

Pediatric obesity. An overview of etiology and treatment

Glucagon-like peptide-1 analog therapy in rare genetic diseases: monogenic obesity, monogenic diabetes, and spinal muscular atrophy

Current and future state of pharmacological management of pediatric obesity

Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity

The Genetics of Obesity

The genetics of childhood obesity and interaction with dietary macronutrients

Anti‐Obesity Medication in the Management of Children and Adolescents With Obesity: Recent Developments and Research Gaps

Pharmacotherapy and Weight-Loss Supplements for Treatment of Paediatric Obesity

Childhood and Adolescent Obesity: A Review

Clinical phenotypes of adults with monogenic and syndromic genetic obesity